Targeting alveolar type II cell dysfunction in idiopathic pulmonary fibrosis: Molecular mechanisms and emerging therapeutic strategies (Review)
International Journal of Molecular Medicine · 13.07.2026 · 58 (3) · 1-11
DOI: 10.3892/ijmm.2026.5927 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 13.07.2026. Verfasst von Tianhao Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Alveolar Epithelial Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a fatal and progressive form of interstitial lung pathology. It is characterized by the relentless replacement of functional alveolar epithelium by aberrant fibroblasts and excessive extracellular matrix deposition, resulting in respiratory failure. Currently, the treatment options for this disease are limited. Approved antifibrotic agents primarily slow disease progression by inhibiting fibroblast proliferation and downstream fibrotic pathways; however, they do not halt or reverse the underlying pathology. Recent studies have elucidated the proliferation and differentiation characteristics of type II alveolar epithelial (AT2) cells, identifying them as facultative stem cells of the distal lung with significant therapeutic potential in IPF. However, there are certain limitations in clinical translation. This review comprehensively summarizes the regulatory pathways governing AT2 proliferation and differentiation, and investigates key pathogenic drivers of IPF, including cellular senescence and mechanical tension. Furthermore, it evaluates current treatment strategies and methods to facilitate safer, more effective clinical delay or even reversal of pulmonary fibrosis by identifying or improving existing therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China.
Zitieren
APA
Xie, T., Hu, K., Pan, S., Tong, X., Huang, H., Ding, H., & Zhao, J. (2026). Targeting alveolar type II cell dysfunction in idiopathic pulmonary fibrosis: Molecular mechanisms and emerging therapeutic strategies (Review). International Journal of Molecular Medicine, 58(3), 1-11. https://doi.org/10.3892/ijmm.2026.5927
Vancouver
Xie T, Hu K, Pan S, Tong X, Huang H, Ding H, et al. Targeting alveolar type II cell dysfunction in idiopathic pulmonary fibrosis: Molecular mechanisms and emerging therapeutic strategies (Review). International Journal of Molecular Medicine. 2026;58(3):1-11. doi:10.3892/ijmm.2026.5927
BibTeX
@article{Xie2026,
author = {Xie, Tianhao and Hu, Kang and Pan, Shu and Tong, Xin and Huang, Haitong and Ding, Hao and Zhao, Jun},
title = {Targeting alveolar type II cell dysfunction in idiopathic pulmonary fibrosis: Molecular mechanisms and emerging therapeutic strategies (Review)},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {58},
number = {3},
pages = {1--11},
doi = {10.3892/ijmm.2026.5927}
}
EUVIMED